Navidea Biopharmaceuticals, Inc. (NAVB) Q2 2012 Earnings Call August 7, 2012 8:00 AM ET Executives Brent Larson – SVP, CFO, Treasurer and Secretary Mark Pykett – President and CEO Fred Cope – SVP, Pharmaceutical Research and Clinical Development Tom Tulip – EVP and Chief Business Officer Analysts Charles Duncan – JMP Securities Kevin DeGeeter – Ladenburg Thalmann Mike King – Rodman & Renshaw Stephen Dunn – Life Tech Capital Steve Brozak – WBB Securities Dalton Chandler – Needham & Co Spencer Nam – ThinkEquity PresentationOperator
Greetings and welcome to the Navidea Biopharmaceuticals, Incorporated Second Quarter 2012 Conference Call. At that time, all participants are in a listen-only mode. A brief question-and-answer session will follow the following presentation. (Operator Instructions) As a reminder, this conference is being recorded. Also management would like to alert you that today’s conference will be no more than one hour in duration. It is now my pleasure at this time to introduce your host, Brent Larson, CFO of Navidea Biopharmaceuticals, Incorporated. Thank you, Mr. Larson. You may now begin. Brent Larson Thank you, Rob. Good morning, everyone. My name, as Rob said, is Brent Larson. I’m the CFO of Navidea Biopharmaceuticals, and I’ll be moderating this morning’s call. Before we get started with the formal comments, we’d like to remind you that during the course of this call management may make projections or other forward-looking remarks regarding future events or the future financial performance of the company. It’s important to note that such statements about Navidea’s estimated or anticipated future results or other non-historical facts are forward-looking statements and reflect Navidea’s current perspective on existing trends and information. Navidea disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Navidea’s current expectations depending on a number of factors affecting Navidea’s business.